ACC Annual Scientific Session In Brief
This article was originally published in The Gray Sheet
Executive Summary
COMPASS-HF: Remote monitoring with Medtronic's investigational Chronicle implantable hemodynamic monitor (IHM) is associated with 41% fewer heart-failure related hospitalizations compared with optimal medical management alone in the 274-patient, 28-center randomized COMPASS-HF (Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure) study. Enrollees had NYHA Class III or IV heart failure and made at least one heart failure-related hospital trip in the last six months. Robert Bourge, MD, University of Alabama-Birmingham, presented the study results at the American College of Cardiology Annual Scientific Session in Orlando March 8...
You may also be interested in...
Cardiology News In Brief
Heart CARE for diabetics: Updated results from Medtronic's 813-patient CARE-HF study finds Medtronic's cardiac resynchronization therapy (CRT) is equally effective for diabetic and nondiabetic heart failure patients. CRT reduced the all-cause mortality rate in diabetic patients by 39%, compared with a 40% reduction in nondiabetics, the firm reported Sept. 3 at the European Society of Cardiology/World Congress of Cardiology 2006 meeting in Barcelona. Overall, Medtronic's InSync CRT products reduced the risk of heart failure death by 45% and sudden cardiac death by 53% in the study, which randomized patients to medical management with and without CRT, with an average follow-up period of about 36 months (1"The Gray Sheet" March 14, 2005, p. 7)...
Cardiology News In Brief
Heart CARE for diabetics: Updated results from Medtronic's 813-patient CARE-HF study finds Medtronic's cardiac resynchronization therapy (CRT) is equally effective for diabetic and nondiabetic heart failure patients. CRT reduced the all-cause mortality rate in diabetic patients by 39%, compared with a 40% reduction in nondiabetics, the firm reported Sept. 3 at the European Society of Cardiology/World Congress of Cardiology 2006 meeting in Barcelona. Overall, Medtronic's InSync CRT products reduced the risk of heart failure death by 45% and sudden cardiac death by 53% in the study, which randomized patients to medical management with and without CRT, with an average follow-up period of about 36 months (1"The Gray Sheet" March 14, 2005, p. 7)...
CRT-D May Reap Higher CE Ratio Than Defibrillation Alone – Annals Editorial
Implantable cardioverter defibrillators with resynchronization (CRT-D) are likely to prove more cost-effective than ICD therapy alone for patients with moderate-to-severe heart failure, according to Stephen Pauker, MD, et al., Tufts University